D
Arcellx, Inc. ACLX
$69.05 $1.351.99% NASDAQ
Recommendation
Prev Close
$67.70
Volume
431,795
Avg Vol (90D)
853,903
Market Cap
$3.91B
Dividend & Yield
--
52-Week Range
$47.86 - $94.07
P/E (TTM)
--
EPS (TTM)
-$3.92
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Arcellx (ACLX) Valuation After FDA Draft Guidance And 2026 Tandem CAR T Data
1/22/2026 - Simply Wall St
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access ...
1/21/2026 - GuruFocus
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
1/21/2026 - Business Wire
Arcellx (ACLX) Is Up 8.1% After FDA Eases Myeloma Trial Endpoints With New MRD Guidance
1/21/2026 - Simply Wall St
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
1/21/2026 - Zacks Investment Research
FDA Guidance Boosts Arcellx (ACLX) and Legend Biotech (LEGN) Shares
1/20/2026 - GuruFocus
Bullish Two Hundred Day Moving Average Cross - ACLX
1/20/2026 - Nasdaq News: Markets
Bullish Two Hundred Day Moving Average Cross - ACLX
1/20/2026 - Market News Video
Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials
1/20/2026 - SeekingAlpha.com: All News
Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials
1/20/2026 - Seeking Alpha - Healthcare
Marquette Asset Management, LLC Sells 22 Shares of Arcellx Inc (ACLX)
1/19/2026 - GuruFocus
Interesting ACLX Put And Call Options For March 20th
1/16/2026 - Nasdaq News: Markets
Interesting ACLX Put And Call Options For March 20th
1/16/2026 - Stock Options Channel
This Insider Has Just Sold Shares In Arcellx
1/16/2026 - Simply Wall St
Christopher Heery Sells 5,882 Shares of Arcellx (NASDAQ:ACLX) Stock
1/15/2026 - MarketBeat
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells $393,303.65 in Stock
1/15/2026 - Ticker Report
Assessing Arcellx (ACLX) Valuation After Strong Myeloma Data And Fresh Analyst Optimism
1/15/2026 - Simply Wall St
Christopher Heery Sells 5,882 Shares of Arcellx (NASDAQ:ACLX) Stock
1/15/2026 - MarketBeat
Arcellx (ACLX, $66.75) entered Uptrend as Momentum indicator ascends above 0 level on Jan 13, 2026
1/14/2026 - Tickeron - Stocks
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells 7,437 Shares of Stock
1/14/2026 - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Moderate Buy" from Analysts
1/14/2026 - MarketBeat
Arcellx (NASDAQ:ACLX) Insider Sells $487,197.87 in Stock
1/14/2026 - Ticker Report
Arcellx (NASDAQ:ACLX) Insider Sells $487,197.87 in Stock
1/14/2026 - MarketBeat
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells $393,303.65 in Stock
1/13/2026 - MarketBeat
Christopher Heery Sells 6,131 Shares of Arcellx (NASDAQ:ACLX) Stock
1/13/2026 - MarketBeat
Income Statement
Total Revenue (TTM)
$35.90M
EBITDA (TTM)
-$235.73M
EBIT (TTM)
-$242.55M
Net Income (TTM)
-$217.90M
Balance Sheet
Total Assets (Q)
$655.92M
Total Debt (Q)
$51.79M
Total Liabilities (Q)
$215.14M
Book Value Per Share (Q)
$7.63
Cash Flow
Cash from Operations (TTM)
-$198.11M
Cash from Investing (TTM)
$24.38M
Cash from Financing (TTM)
$90.88M
Net Change in Cash (TTM)
-$82.85M
Filings
Filing Date
Wednesday, November 5, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.20
7-Day Total Return
-1.16%
30-Day Total Return
-4.07%
60-Day Total Return
-21.08%
90-Day Total Return
-10.73%
Year to Date Total Return
9.01%
1-Year Total Return
9.61%
2-Year Total Return
22.95%
3-Year Total Return
113.98%
5-Year Total Return
--
52-week Low
May 07, 2025 - $47.86
52-week High
Oct 16, 2025 - $94.07
Valuation
Market Cap
$3.91B - Mid Cap
Enterprise Value
$3.39B
Price/Sales (TTM)
106.73
Price/Book (Q)
8.87
Dividends and Shares
Shares Outstanding
56.59M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.arcellx.com
Phone Number
240 327 0630
Address
800 Bridge Parkway
Redwood City, CA 94065
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead... more
NASDAQ 01/26/2026 3:07PM Eastern Quotes delayed